Categories News Press Releases Archives 2025 June May April March February January 2024 December November October September August July June May April March February January 2023 December November October September August July June April March February January 2022 December November October September August June May March February January 2021 December November October September August May April February Apr 04 FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations Read More Share:| | | Dec 16 Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial Read More Share:| | |